When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in a study assessing Japanese patients with different subtypes of neovascular ...
The 5 products are 1-5: Yesafili (aflibercept-jbvf) in May 2024 Opuviz (aflibercept-yszy) in May 2024 Ahzantive (aflibercept-mrbb) in July 2024 Enzeevu (aflibercept-abzv) in August 2024 Pavblu ...
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback